Health and Life Sciences - AI's Foundational Shift from Models to Molecules | PiTech Solutions Podcast

Health and Life Sciences: AI's Foundational Shift from Models to Molecules | PiTech Solutions PodcastThis week, Mike and Laura examine an inflection point for health and life sciences as artificial intelligence moves from pilot projects to foundational infrastructure across drug discovery, clinical trials, and regulatory review. They unpack the most consequential announcements of the past week and what they mean for C suite leaders in pharma, biotech, and healthcare.OpenAI Enters Drug Discovery with GPT Rosalind. On April sixteenth, OpenAI launched a new model purpose built for biochemistry and genomics, squaring off against Google's Isomorphic Labs. Combined with Anthropic's four hundred million dollar acquisition of Coefficient Bio, frontier AI labs are now placing direct bets on the life sciences stack.Eli Lilly's LillyPod and the Compute Arms Race. Lilly inaugurated the world's first NVIDIA DGX SuperPOD with DGX B three hundred systems, delivering over nine thousand petaflops of AI performance. We explore why industry leaders are building AI native operating models now and letting regulation catch up.FDA and EMA Align on AI Principles. With regulators now demanding transparency, lifecycle controls, and explainable logic, we discuss what a mature AI governance framework looks like and why boards need to own this topic directly.From Models to Molecules. The industry language has shifted. The first AI designed drug candidates are approaching phase three milestones, and platformization plus AI fluency are redrawing the clinical trial value chain. We also cover biosecurity concerns, AWS Amazon Bio Discovery, and why only twenty percent of biopharma companies are considered digitally maturing.To learn more about how PiTech Solutions helps regulated industries navigate AI driven transformation with trust as the ultimate competitive advantage, visit pitechsol.com.#HealthAndLifeSciences #ArtificialIntelligence #DrugDiscovery #ClinicalTrials #AIGovernance